Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
FAAH CRISPR/Cas9 KO Plasmid (h): sc-402470
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FAAH CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the FAAH genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FAAH Antibody (27-Y): sc-100739
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FAAH CRISPR/Cas9 KO Plasmid (h) | sc-402470 | 20 µg | $397.00 |
Overview
FAAH (fatty acid amide hydrolase) is a membrane-associated serine hydrolase that terminates signaling by hydrolyzing bioactive fatty acid amides, including the endocannabinoid anandamide and related N-acylethanolamines. By controlling lipid mediator turnover, FAAH modulates endocannabinoid tone, intersects with CB1/CB2 receptor signaling, and influences downstream cAMP/PKA, MAPK, and calcium-dependent pathways. FAAH activity also shapes broader lipid metabolic networks that govern cellular stress responses and neurotransmission. Altered FAAH expression or function has been associated with dysregulated neuroinflammatory and pain-processing pathways and is studied in the context of neuropsychiatric and metabolic phenotypes.
FAAH CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the FAAH gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the FAAH together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the FAAH open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish FAAH protein expression.
This CRISPR knockout system enables efficient generation of FAAH-deficient cell models for investigation of FAAH signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting FAAH exon(s) critical for FAAH function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple FAAH genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by FAAH CRISPR/Cas9 KO Plasmid (h) and FAAH CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the FAAH locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by FAAH HDR Plasmid (h) and FAAH HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by FAAH homology arms to support homology-directed repair at defined FAAH target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.